We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder (MATRIX)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00224146
First Posted: September 22, 2005
Last Update Posted: November 30, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Watson Pharmaceuticals
September 14, 2005
September 22, 2005
November 30, 2011
May 2004
May 2005   (Final data collection date for primary outcome measure)
Change in health-related quality of life
Same as current
Complete list of historical versions of study NCT00224146 on ClinicalTrials.gov Archive Site
  • Change in other outcomes such as:
  • depression
  • work productivity
  • participant satisfaction
  • effect of enhanced patient education on any of the above outcomes
  • Change in other outcomes such as:
  • depression
  • work productivity
  • participant satisfaction
  • effect of enhanced patient on any of the above outcomes
Not Provided
Not Provided
 
Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder
Multicenter Assessment of Transdermal Therapy in Overactive Bladder With Oxybutynin TDS (MATRIX)
This study evaluates changes in health related quality of life outcomes in patients using Oxytrol(r)
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Overactive Bladder
  • Urinary Incontinence
  • Quality of Life
Drug: oxybutynin transdermal delivery system (Oxytrol(r))
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2878
May 2005
May 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult patients with one or more symptom of overactive bladder, including urge urinary incontinence, urgency and/or frequency

Exclusion Criteria:

  • Patients for whom Oxytrol(r) is contraindicated.
  • Patients treated with Oxytrol(r) prior to participation in this study.
  • Patients residing in long-term care facilities or nursing homes.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00224146
OXY0402
MATRIX
Not Provided
Not Provided
Not Provided
Watson Pharmaceuticals
Watson Pharmaceuticals
Not Provided
Study Director: Naomi V. Dahl, PharmD Watson Laboratories, Inc.
Watson Pharmaceuticals
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP